Abstract 15440: Clinical Outcomes of Drug-Coated Balloon Angioplasty Compared with Drug-Eluting Stents in Coronary Bifurcation Lesions: An Updated Systematic Review and Meta-Analysis
Abstract
Background: The optimal percutaneous coronary intervention strategy for coronary bifurcation lesions remains uncertain. Drug-coated balloon (DCB) angioplasty offers a stent-less approach that may preserve vessel physiology and reduce metal burden. We performed an updated systematic review and meta-analysis comparing DCB with drug-eluting stents (DES) for coronary bifurcation interventions. Methods: Following PRISMA guidelines and PROSPERO registration (CRD420261417555), PubMed, Scopus, and Embase were searched from inception to June 2026. Randomized and observational studies comparing DCB and DES in coronary bifurcation lesions were included. Random-effects meta-analyses generated pooled risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Outcomes included major adverse cardiovascular events (MACE), target vessel myocardial infarction (TV-MI), target lesion revascularization (TLR), target vessel revascularization (TVR), restenosis, cardiovascular death, late lumen loss (LLL), and minimal luminal diameter (MLD). Results: Seven studies involving 3,723 patients (DCB: 1,768; DES: 1,995) were included. DCB significantly reduced TV-MI (RR 0.53, 95% CI 0.34-0.83; I 2 =0%; p=0.006) and MACE (RR 0.64, 95% CI 0.52-0.80; I 2 =0%; p<0.001). No significant differences were observed for TLR (RR 0.63, 95% CI 0.26-1.48; I 2 =73.1%; p=0.287), restenosis (RR 0.34, 95% CI 0.07-1.55; I 2 =58.3%; p=0.163), or cardiovascular death (RR 0.97, 95% CI 0.70-1.34; I 2 =0%; p=0.851). Side-branch MLD was similar between groups (MD 0.06 mm, 95% CI –0.27 to 0.39; I 2 =95.5%; p=0.729), whereas side-branch LLL was significantly lower with DCB (MD –0.29 mm, 95% CI –0.54 to –0.04; I 2 =83.4%; p=0.022). Main-vessel MLD (MD 0.13 mm, 95% CI –0.34 to 0.60; I 2 =98.3%; p=0.558) and main-vessel LLL (MD –0.07 mm, 95% CI –0.18 to 0.04; I 2 =77.2%; p=0.210) were comparable. TVR was higher with DCB (RR 2.56, 95% CI 1.19-5.52; I 2 =0%; p=0.016), although this finding was based on only two studies. Conclusions: In coronary bifurcation lesions, DCB angioplasty was associated with lower rates of MACE and TV-MI, similar rates of TLR, restenosis, cardiovascular mortality, and comparable main-vessel angiographic outcomes versus DES. DCB also reduced side-branch late lumen loss, supporting its role as a promising alternative to DES in selected bifurcation lesions. Larger randomized trials with long-term follow-up are needed.